gefitinib has been researched along with bms 754807 in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (bms 754807) | Trials (bms 754807) | Recent Studies (post-2010) (bms 754807) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 55 | 0 | 46 |
| Protein | Taxonomy | gefitinib (IC50) | bms 754807 (IC50) |
|---|---|---|---|
| G1/S-specific cyclin-E2 | Homo sapiens (human) | 1.035 | |
| High affinity nerve growth factor receptor | Homo sapiens (human) | 0.007 | |
| Insulin receptor | Homo sapiens (human) | 0.0017 | |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | 0.0036 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 7 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.0021 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 1.035 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 1.035 | |
| RAC-alpha serine/threonine-protein kinase | Mus musculus (house mouse) | 0.022 | |
| BDNF/NT-3 growth factors receptor | Homo sapiens (human) | 0.004 | |
| Insulin-like growth factor 1 receptor | Mus musculus (house mouse) | 0.013 | |
| Serine/threonine-protein kinase LMTK3 | Homo sapiens (human) | 3.161 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Ahn, JH; Kim, EJ; Kim, SW; Kim, SY; Lee, HJ; Lee, SJ; Moon, DH; Oh, SJ; Ryu, JS | 1 |
2 other study(ies) available for gefitinib and bms 754807
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [(18)F]fluorothymidine-positron emission tomography.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fluorine Radioisotopes; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Pilot Projects; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Receptor, IGF Type 1; Thymidine; Triazines; Tumor Burden | 2013 |